Washington D.C. Jan. 6, 2017. The Securities and Exchange Commission announced an award of more than $5.5 million paid to a whistleblower who provided critical information that helped the SEC uncover an ongoing scheme. Continue Reading
On December 29, 2016, the Justice Department announced that it had reached the final resolutions under the Swiss Bank Program. The Swiss Bank Program was put in place after a massive tax evasion scheme at Swiss bank UBS was exposed by Bradley Birkenfeld. The former international banker and wealth manager with UBS recently released Lucifer’s Banker: The Untold Story of How I Destroyed Swiss Bank Secrecy detailing his journey as he took on the Swiss banking industry. Continue Reading
The SEC Office of the Whistleblower posts Notices of Covered Action where a final judgment or order, by itself or together with other prior judgments or orders in the same action issued after July 21, 2010, results in monetary sanctions exceeding $1 million. Subject to the Final Rules, individuals who voluntarily provided the Commission with original information after July 21, 2010 that led to the successful enforcement of a covered action listed below are eligible to apply for a whistleblower award. Once a Notice of Covered Action is posted by the SEC, individuals have 90 calendar days to apply for an award.
At the end of another year we want to pause and thank you for taking the time to read The Whistleblower Blog. This year saw a new record for pageviews on content as well as an over 100% increase in readers. In addition to the readers, we want to extend a special thanks to our contributors who created content highlighting important news, legal developments and policy issues critical to whistleblowers and their advocates around the world.
If you’d like to be the first to know when we post a new blog post, remember you can get notifications by subscribing to our RSS Feed here. Or you can use the box at the top right to receive our posts via email.
Here are the top 10 posts from 2016:
On December 15, 2016, the Department of Justice announced that Forest Laboratories LLC (Forest), located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., have agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic®, Savella®, and Namenda®.
On November 23, 2016 the Justice Department announced that Bechtel National Inc., Bechtel Corp., URS Corp. (predecessor in interest to AECOM Global II LLC) and URS Energy and Construction Inc. (now known as AECOM Energy and Construction Inc.) agreed to pay $125 million to resolve allegations under the False Claims Act that they made false statements and claims to the Department of Energy (DOE) by charging DOE for deficient nuclear quality materials, services, and testing that was provided at the Waste Treatment Plant (WTP) at DOE’s Hanford Site near Richland, Washington. Continue Reading
The Securities and Exchange Commission announced yesterday that Teva Pharmaceutical Industries Limited has agreed to pay more than $519 million to settle parallel civil and criminal charges that it violated the Foreign Corrupt Practices Act by paying bribes to foreign government officials in Russia, Ukraine, and Mexico. Continue Reading
The Administrative Review Board issues final agency decisions for the Secretary of Labor in cases arising under a wide range of worker protection laws, primarily involving environmental, transportation, and securities whistleblower protection. The below list includes decisions of the Administrative Review Board from November – December 2016 as reported in the USDOL/OALJ Reporter: Continue Reading
The Securities and Exchange Commission today announced that a Brazilian-based petrochemical manufacturer whose stock trades in the U.S. markets has agreed to settle charges that it created false books and records to conceal millions of dollars in illicit bribes paid to Brazilian government officials to win or retain business. Continue Reading
Pennsylvania-based medical device manufacturer Biocompatibles Inc., a subsidiary of BTG plc, plead guilty on November 7, 2016 to misbranding its embolic device LC Bead and will pay more than $36 million to resolve criminal and civil liability arising out of its illegal conduct. LC Bead is used to treat liver cancer, among other diseases. Continue Reading